The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review
Nearly 35 million people worldwide live with Alzheimer’s disease (AD). The prevalence of the disease is expected to rise two-fold by 2050. With only symptomatic treatment options available, it is essential to understand the developments and existing evidence that aims to target brain pathology and d...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/1/1 |
| _version_ | 1828057481517989888 |
|---|---|
| author | Anum Rasheed Ahmad Bin Zaheer Aqsa Munawwar Zouina Sarfraz Azza Sarfraz Karla Robles-Velasco Ivan Cherrez-Ojeda |
| author_facet | Anum Rasheed Ahmad Bin Zaheer Aqsa Munawwar Zouina Sarfraz Azza Sarfraz Karla Robles-Velasco Ivan Cherrez-Ojeda |
| author_sort | Anum Rasheed |
| collection | DOAJ |
| description | Nearly 35 million people worldwide live with Alzheimer’s disease (AD). The prevalence of the disease is expected to rise two-fold by 2050. With only symptomatic treatment options available, it is essential to understand the developments and existing evidence that aims to target brain pathology and dementia outcomes. This scoping systematic review aimed to collate existing evidence of CT1812 for use in patients with AD and summarize the methodologies of ongoing trials. Adhering to PRISMA Statement 2020 guidelines, PubMed/MEDLINE, Embase, Cochrane, and ClinicalTrials.gov were systematically searched through up to 15 November 2022 by applying the following keywords: CT1812, Alzheimer’s disease, dementia, and/or sigma-2 receptor. Three completed clinical trials were included along with three ongoing records of clinical trials. The three completed trials were in Phases I and II of testing. The sample size across all three trials was 135. CT1812 reached endpoints across the trials and obtained a maximum concentration in the cerebrospinal fluid with 97–98% receptor occupancy. The findings of this systematic review must be used with caution as the results, while mostly favorable so far, must be replicated in higher-powered, placebo-controlled Phase II–III trials. |
| first_indexed | 2024-04-10T21:13:21Z |
| format | Article |
| id | doaj.art-a176f98f7812414c8acb70e62bfddda7 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-04-10T21:13:21Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-a176f98f7812414c8acb70e62bfddda72023-01-20T15:10:21ZengMDPI AGLife2075-17292022-12-01131110.3390/life13010001The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic ReviewAnum Rasheed0Ahmad Bin Zaheer1Aqsa Munawwar2Zouina Sarfraz3Azza Sarfraz4Karla Robles-Velasco5Ivan Cherrez-Ojeda6Department of Research, Services Institute of Medical Sciences, Lahore 54000, PakistanDepartment of Research, Al Nafees Medical College and Hospital, Isra University, Islamabad 44000, PakistanDepartment of Research, Services Institute of Medical Sciences, Lahore 54000, PakistanDepartment of Research and Publications, Fatima Jinnah Medical University, Lahore 54000, PakistanDepartment of Pediatrics and Child Health, The Aga Khan University, Karachi 74000, PakistanDepartment of Allergy, Immunology & Pulmonary Medicine, Universidad Espíritu Santo, Samborondón 092301, EcuadorDepartment of Allergy, Immunology & Pulmonary Medicine, Universidad Espíritu Santo, Samborondón 092301, EcuadorNearly 35 million people worldwide live with Alzheimer’s disease (AD). The prevalence of the disease is expected to rise two-fold by 2050. With only symptomatic treatment options available, it is essential to understand the developments and existing evidence that aims to target brain pathology and dementia outcomes. This scoping systematic review aimed to collate existing evidence of CT1812 for use in patients with AD and summarize the methodologies of ongoing trials. Adhering to PRISMA Statement 2020 guidelines, PubMed/MEDLINE, Embase, Cochrane, and ClinicalTrials.gov were systematically searched through up to 15 November 2022 by applying the following keywords: CT1812, Alzheimer’s disease, dementia, and/or sigma-2 receptor. Three completed clinical trials were included along with three ongoing records of clinical trials. The three completed trials were in Phases I and II of testing. The sample size across all three trials was 135. CT1812 reached endpoints across the trials and obtained a maximum concentration in the cerebrospinal fluid with 97–98% receptor occupancy. The findings of this systematic review must be used with caution as the results, while mostly favorable so far, must be replicated in higher-powered, placebo-controlled Phase II–III trials.https://www.mdpi.com/2075-1729/13/1/1CT1812Elaytasigma-2therapeutic candidateAlzheimer’s diseaseclinical trials |
| spellingShingle | Anum Rasheed Ahmad Bin Zaheer Aqsa Munawwar Zouina Sarfraz Azza Sarfraz Karla Robles-Velasco Ivan Cherrez-Ojeda The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review Life CT1812 Elayta sigma-2 therapeutic candidate Alzheimer’s disease clinical trials |
| title | The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review |
| title_full | The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review |
| title_fullStr | The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review |
| title_full_unstemmed | The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review |
| title_short | The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review |
| title_sort | allosteric antagonist of the sigma 2 receptors elayta ct1812 as a therapeutic candidate for mild to moderate alzheimer s disease a scoping systematic review |
| topic | CT1812 Elayta sigma-2 therapeutic candidate Alzheimer’s disease clinical trials |
| url | https://www.mdpi.com/2075-1729/13/1/1 |
| work_keys_str_mv | AT anumrasheed theallostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT ahmadbinzaheer theallostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT aqsamunawwar theallostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT zouinasarfraz theallostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT azzasarfraz theallostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT karlaroblesvelasco theallostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT ivancherrezojeda theallostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT anumrasheed allostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT ahmadbinzaheer allostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT aqsamunawwar allostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT zouinasarfraz allostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT azzasarfraz allostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT karlaroblesvelasco allostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview AT ivancherrezojeda allostericantagonistofthesigma2receptorselaytact1812asatherapeuticcandidateformildtomoderatealzheimersdiseaseascopingsystematicreview |